Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease.
Chromoendoscopy
Colonoscopy
Crohn’s disease
Dye spray
Dysplasia
Inflammatory bowel disease
Neoplasia; Screening
Surveillance
Ulcerative colitis
White light endoscopy
Journal
Journal of the Canadian Association of Gastroenterology
ISSN: 2515-2092
Titre abrégé: J Can Assoc Gastroenterol
Pays: England
ID NLM: 101738684
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
16
2
2023
Statut:
epublish
Résumé
Pancolonic dye spray chromoendoscopy (DCE) is used as an adjunct to white light endoscopy (WLE) to enhance the detection and delineation of ill-defined neoplastic (dysplastic) lesions in persons with colonic inflammatory bowel diseases (cIBD). We evaluated the utility of DCE as follow-up to high-definition WLE (HD-WLE) to "unmask" and/or facilitate endoscopic resection of neoplastic lesions. We retrospectively studied persons with cIBD who underwent DCE as follow-up to HD-WLE between 2013 and 2020. We describe neoplastic findings and management during HD-WLE and DCE exams and report outcomes from post-DCE surveillance exams. Twenty-four persons were studied (mean age 56.7 ± 13.8 years, 50.0% male, 70.8% ulcerative colitis, mean disease duration 18.0 ± 11.0 years). Overall, 32 visible neoplastic lesions were unmasked during DCE, of which 24 were endoscopically resected. DCE facilitated the diagnosis of two cancers. Among 17 persons referred for evaluation of "invisible" neoplasia (detected in non-targeted biopsies) during HD-WLE, DCE identified neoplastic lesions at the same site in eight persons and a different site in four persons. Among seven persons referred for ill-defined visible neoplasia, DCE facilitated complete endoscopic resection in four individuals, whereas two individuals required colectomy for a diagnosis of cancer. Among 19 individuals with post-DCE surveillance, five developed new visible neoplastic lesions, including one high-grade neoplasia which was completely resected. In our cohort, DCE aided in unmasking invisible neoplasia and facilitated endoscopic resection of ill-defined neoplasia, suggesting that it is a useful surveillance tool in selected persons with cIBD. Large prospective studies are needed to validate these findings.
Sections du résumé
Background
UNASSIGNED
Pancolonic dye spray chromoendoscopy (DCE) is used as an adjunct to white light endoscopy (WLE) to enhance the detection and delineation of ill-defined neoplastic (dysplastic) lesions in persons with colonic inflammatory bowel diseases (cIBD). We evaluated the utility of DCE as follow-up to high-definition WLE (HD-WLE) to "unmask" and/or facilitate endoscopic resection of neoplastic lesions.
Methods
UNASSIGNED
We retrospectively studied persons with cIBD who underwent DCE as follow-up to HD-WLE between 2013 and 2020. We describe neoplastic findings and management during HD-WLE and DCE exams and report outcomes from post-DCE surveillance exams.
Results
UNASSIGNED
Twenty-four persons were studied (mean age 56.7 ± 13.8 years, 50.0% male, 70.8% ulcerative colitis, mean disease duration 18.0 ± 11.0 years). Overall, 32 visible neoplastic lesions were unmasked during DCE, of which 24 were endoscopically resected. DCE facilitated the diagnosis of two cancers. Among 17 persons referred for evaluation of "invisible" neoplasia (detected in non-targeted biopsies) during HD-WLE, DCE identified neoplastic lesions at the same site in eight persons and a different site in four persons. Among seven persons referred for ill-defined visible neoplasia, DCE facilitated complete endoscopic resection in four individuals, whereas two individuals required colectomy for a diagnosis of cancer. Among 19 individuals with post-DCE surveillance, five developed new visible neoplastic lesions, including one high-grade neoplasia which was completely resected.
Conclusions
UNASSIGNED
In our cohort, DCE aided in unmasking invisible neoplasia and facilitated endoscopic resection of ill-defined neoplasia, suggesting that it is a useful surveillance tool in selected persons with cIBD. Large prospective studies are needed to validate these findings.
Identifiants
pubmed: 36789142
doi: 10.1093/jcag/gwac024
pii: gwac024
pmc: PMC9915055
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37-41Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
Références
Gastrointest Endosc. 2017 Dec;86(6):949-951
pubmed: 28974381
Gastroenterology. 1998 Dec;115(6):1566-73
pubmed: 9834286
Inflamm Bowel Dis. 2020 Aug 20;26(9):1319-1329
pubmed: 32034916
Lancet. 1994 Jan 8;343(8889):71-4
pubmed: 7903776
Gastroenterology. 2012 Aug;143(2):382-9
pubmed: 22609382
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Inflamm Bowel Dis. 2011 May;17(5):1101-7
pubmed: 20853434
Endosc Int Open. 2020 May;8(5):E578-E590
pubmed: 32355874
Gut. 1994 Oct;35(10):1419-23
pubmed: 7959198
Gastrointest Endosc. 2013 Mar;77(3):351-9
pubmed: 23317581
Gut. 2018 Jun;67(6):1087-1094
pubmed: 28698230
J Dig Dis. 2019 Apr;20(4):206-214
pubmed: 30756472
Histopathology. 2021 May;78(6):814-830
pubmed: 33155325
Gastroenterology. 2015 Mar;148(3):639-651.e28
pubmed: 25702852
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):789-99
pubmed: 23448792
Gastroenterology. 2021 Sep;161(3):1043-1051.e4
pubmed: 34416977
Oncol Rep. 2006 Nov;16(5):1123-9
pubmed: 17016603
Gastroenterology. 2022 Mar;162(3):715-730.e3
pubmed: 34757143
Cancer. 2001 Feb 15;91(4):854-62
pubmed: 11241255
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Gastroenterol Clin North Am. 2012 Jun;41(2):291-302
pubmed: 22500518
Colorectal Dis. 2014 Sep;16(9):710-8; discussion 718
pubmed: 24836541
Gastrointest Endosc. 2015 May;81(5):1101-21.e1-13
pubmed: 25800660
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1174-7
pubmed: 7577016
Gastroenterology. 1985 Dec;89(6):1342-6
pubmed: 4054527
Gastrointest Endosc Clin N Am. 2014 Jul;24(3):327-35
pubmed: 24975524
Gastroenterology. 1992 Apr;102(4 Pt 1):1149-54
pubmed: 1551524
Endosc Int Open. 2017 Oct;5(10):E974-E979
pubmed: 28983504
Gastroenterology. 1992 Nov;103(5):1611-20
pubmed: 1426881
Inflamm Bowel Dis. 2005 Mar;11(3):314-21
pubmed: 15735438
Inflamm Intest Dis. 2021 Feb;6(1):25-31
pubmed: 33850836
Gastrointest Endosc. 2019 Aug;90(2):186-195.e1
pubmed: 31009609
Endoscopy. 2019 Dec;51(12):1155-1179
pubmed: 31711241
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Gastrointest Endosc Clin N Am. 2014 Jul;24(3):455-68
pubmed: 24975536